PPT-The Changing Landscape of Diabetes Therapy for Cardiovascular Risk Reduction

Author : faustina-dinatale | Published Date : 2019-11-22

The Changing Landscape of Diabetes Therapy for Cardiovascular Risk Reduction Paull Rukavina RPh MTM provider Fairview Apple Valley and Highland Park Clinics OBJECTIVES

Presentation Embed Code

Download Presentation

Download Presentation The PPT/PDF document "The Changing Landscape of Diabetes Thera..." is the property of its rightful owner. Permission is granted to download and print the materials on this website for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.

The Changing Landscape of Diabetes Therapy for Cardiovascular Risk Reduction: Transcript

The Changing Landscape of Diabetes Therapy for Cardiovascular Risk Reduction Paull Rukavina RPh MTM provider Fairview Apple Valley and Highland Park Clinics OBJECTIVES 1 Review ADAAACE Glycemic control Algorithms. د. حسين محمد جمعة . اختصاصي الامراض الباطنة . . البورد العربي . كلية طب الموصل . . . . 2011. . . Gary Michael Idelchik, MD, FACC. April 15, . 2015. Disclosures. I have nothing to disclose.. Outline. What is/are. … . What is Cardiovascular Disease and its manifestations?. What is Coronary Artery Disease (. Optimizing . patient care. William Cromwell, MD, FAHA, FNLA. Chief Medical Officer – LipoScience, Inc.. Chief – Lipoprotein and Metabolic Disorders Institute. Adjunct Associate Professor – Wake Forest University School of Medicine. and Glycemic Treatment Options. Rocky . Mountain/ACP. Internal . Medicine Conference. Banff. , AB. November 22, 2012. David C.W. Lau, MD, PhD, FRCPC. Depts. of Medicine. , . Biochem. . . & . Molec. Deepak L. Bhatt, MD, MPH. Professor . of Medicine, Harvard Medical School. Executive Director of Interventional Cardiovascular Programs. Brigham & Women’s Hospital Heart and Vascular Center. Boston, Massachusetts. Slide 1: . Target. population/question. 2. 09/01/2018. Patients with inflammatory joint disorders, particularly rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis. To update the EULAR 2009 cardiovascular disease (. Evidence Grading System. A. Clear evidence from well-conducted, generalizable RCTs, that are adequately powered, including:. Evidence from a well-conducted multicenter trial or meta-analysis that incorporated quality ratings in the analysis;. www.onlinecjc.com. ). . If your reuse request qualifies as medical institution internal education, you may reuse the material under the following conditions:. You . must cite the Canadian Journal of Cardiology and the Canadian . European Association for the Study of Diabetes. Lisbon, . 13. th. . September 2017. ISRCTN number: 91899513. ClinicalTrials.gov number: . NCT00829660. Study Rationale, Design and Conduct. The Diabetes Burden. MAHTAB NIROOMAND M.D.. Assistant professor of Endocrinology. SBUMS. Tehran 1391/11/19. . Out-line . Pathophysiology. and types of dyslipidemia in diabetic patients. Benefits of lipid- lowering therapy. 2018 ADA GUIDELINES. Dr. . Sanjana. Bhagwat. Moderator : Dr. S. . Jotkar. Diabetes is a complex, chronic illness requiring continuous medical care with multifactorial risk-reduction strategies beyond glycemic control. Lipid Management in Patients with Endocrine. Disorders. An Endocrine Society Clinical Practice. Guideline. AGENDA. Screening and cardiovascular disease risk. Assessment . Type 2 diabetes mellitus . Type 1 diabetes mellitus . Nathan D. Wong, PhD, FACC, FAHA, FNLA, FASPC. Professor and Director. Heart Disease Prevention Program. Division of Cardiology. University of California, Irvine. Editorial Lead, ACC Diabetes and Cardiometabolic Clinical Topic Collection. Sex . Male. Diabetes. . History. T2D, . onset. @45 . yrs. , treatment: . metformin. , . sitagliptin. and . gliclazide. . Organ. . damage. . evaluation. :. Eyes. : No . signs. of . retinopathy.

Download Document

Here is the link to download the presentation.
"The Changing Landscape of Diabetes Therapy for Cardiovascular Risk Reduction"The content belongs to its owner. You may download and print it for personal use, without modification, and keep all copyright notices. By downloading, you agree to these terms.